Pancreatic Cancer Research

ResearcherUniversity of MichiganNo recent work listed

Andrew D. Rhim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5788-0155; OpenAlex author ID A5041384981; NIH RePORTER profile ID 7846770. Sources: funder_awards.

Their work

Papers
29 (first author 4, last author 4)
Trials
0
Grants
2
Labs led
3
Collaborators
182
Papers, trials and grants by year

2012: 1 paper, 1 grant · 2013: 3 papers, 1 grant · 2014: 5 papers · 2015: 3 papers · 2016: 5 papers · 2017: 4 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper

Papers 29

  1. Transfusion of salvaged red blood cells during pancreatic ductal adenocarcinoma operations. First author DOI 10.1093/bjs/znac393↗
  2. A clinical prediction model to assess risk for pancreatic cancer among patients with prediabetes. Co-author DOI 10.1097/meg.0000000000002052↗
  3. Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2021.108990↗
  4. APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Last author DOI 10.1038/s43018-021-00268-8↗
  5. Ultra-low Input Circulating Tumor DNA Detection by MED-Amp in Early-Stage Pancreatic Cancer Last author DOI 10.1101/2021.03.28.437388↗
  6. Pancreatic Cancer-Related Mutational Burden Is Not Increased in a Patient Cohort With Clinically Severe Chronic Pancreatitis. Last author DOI 10.14309/ctg.0000000000000431↗
  7. Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.jss.2019.04.090↗
  8. Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Co-author DOI 10.1016/j.devcel.2018.05.025↗
  9. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2017.03.022↗
  10. MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Co-author DOI 10.1038/s41467-017-01967-6↗
  11. A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes. Co-author DOI 10.1053/j.gastro.2016.11.046↗
  12. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-312078↗
  13. Adipocytes promote pancreatic cancer cell proliferation via glutamine transfer. Co-author DOI 10.1016/j.bbrep.2016.06.004↗
  14. Ablation of sensory neurons in a genetic model of pancreatic ductal adenocarcinoma slows initiation and progression of cancer. Co-author DOI 10.1073/pnas.1512603113↗
  15. Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report. Co-author DOI 10.1097/mpa.0000000000000705↗
  16. Orthotopic Injection of Pancreatic Cancer Cells. First author DOI 10.1101/pdb.prot078360↗
  17. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-15-0402↗
  18. A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling. Last author DOI 10.1053/j.gastro.2015.10.028↗
  19. Early detection of sporadic pancreatic cancer: summative review. Co-author DOI 10.1097/mpa.0000000000000368↗
  20. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. Co-author DOI 10.1371/journal.pone.0118933↗
  21. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccr.2014.04.021↗
  22. Characterization of microfluidic shear-dependent epithelial cell adhesion molecule immunocapture and enrichment of pancreatic cancer cells from blood cells wit… Co-author DOI 10.1063/1.4890466↗
  23. Molecular biology of pancreatic ductal adenocarcinoma. First author DOI 10.1097/mog.0000000000000104↗
  24. Diagnosis of pernicious anemia and the risk of pancreatic cancer. First author DOI 10.1097/mpa.0000000000000054↗
  25. Neuroplastic changes occur early in the development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-13-2050↗
  26. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Co-author DOI 10.1016/j.celrep.2013.05.036↗
  27. Epithelial to mesenchymal transition and the generation of stem-like cells in pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.01.004↗
  28. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Co-author DOI 10.1158/0008-5472.can-13-1558-t↗
  29. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Co-author DOI 10.1016/j.ccr.2012.04.025↗

Grants 2

  1. Using human circulating pancreas cells as a biomarker for early PDAC AWARD pancan:2013-andrew-rhim-md-using-human-circulating-pancreas-cells-a
  2. Dissecting stromal-epithelial interactions in the adult exocrine pancreas K08DK088945↗

Closest collaborators

The 25 strongest of 182 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert W. Cowan · 4 shared papers, 2015–2021 · strength 0.43
  2. Erica D. Pratt · 3 shared papers, 2017–2021 · strength 0.30
  3. Anirban Maitra · 4 shared papers, 2015–2021 · strength 0.30
  4. Yu‐Xiao Yang · 3 shared papers, 2014–2022 · strength 0.29
  5. Diane M. Simeone · 4 shared papers, 2015–2021 · strength 0.28
  6. Ben Z. Stanger · 6 shared papers, 2012–2016 · strength 0.27
  7. Ben Boursi · 2 shared papers, 2017–2022 · strength 0.24
  8. Ronac Mamtani · 2 shared papers, 2017–2022 · strength 0.24
  9. Melena D. Bellin · 2 shared papers, 2021 · strength 0.22
  10. Kenneth P. Olive · 2 shared papers, 2014–2023 · strength 0.21
  11. Matthew H. G. Katz · 2 shared papers, 2019–2021 · strength 0.18
  12. Michael P. Kim · 2 shared papers, 2019–2021 · strength 0.18
  13. Kazuki N. Sugahara · 1 shared paper, 2023 · strength 0.17
  14. Neha Goel · 1 shared paper, 2023 · strength 0.17
  15. Michael D. Kluger · 1 shared paper, 2023 · strength 0.17
  16. Alexander S. Thomas · 1 shared paper, 2023 · strength 0.17
  17. Beth Schrope · 1 shared paper, 2023 · strength 0.17
  18. John A. Chabot · 1 shared paper, 2023 · strength 0.17
  19. Wooil Kwon · 1 shared paper, 2023 · strength 0.17
  20. Ravikanth Maddipati · 2 shared papers, 2018–2021 · strength 0.15
  21. Nicole M. Aiello · 2 shared papers, 2015–2016 · strength 0.14
  22. Kathleen M. McAndrews · 1 shared paper, 2021 · strength 0.13
  23. Julienne L. Carstens · 1 shared paper, 2021 · strength 0.13
  24. Xiaofeng Zheng · 1 shared paper, 2021 · strength 0.13
  25. Valerie Gunchick · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.